Common Contracts

128 similar Placement Agent Agreement contracts by ONCOSEC MEDICAL Inc, Cell Therapeutics Inc, Novelos Therapeutics, Inc., others

Chardan Capital Markets, LLC
Placement Agent Agreement • March 1st, 2019 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York

This letter (the “Agreement”) constitutes the agreement between Chardan Capital Markets, LLC (“Chardan”) (the “Placement Agent”) and Nanoviricides, Inc. (the “Company”), that Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $.001 per share (the “Common Stock”) and warrants to purchase shares of Common Stock (the “Warrants”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Placement Agent would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents execu

AutoNDA by SimpleDocs
CONFIDENTIAL
Placement Agent Agreement • October 24th, 2017 • ONCOSEC MEDICAL Inc • Pharmaceutical preparations • New York
CONFIDENTIAL OncoSec Medical Incorporated
Placement Agent Agreement • May 24th, 2016 • ONCOSEC MEDICAL Inc • Pharmaceutical preparations • New York
CONFIDENTIAL OncoSec Medical Incorporated
Placement Agent Agreement • November 5th, 2015 • ONCOSEC MEDICAL Inc • Pharmaceutical preparations • New York
ECOBAN SECURITIES CORPORATION 521 Fifth Avenue, Suite 630, New York, N.Y. 10175 TEL (212) 805-8300 × FAX (212) 805-8395
Placement Agent Agreement • July 3rd, 2014 • United States Antimony Corp • Primary smelting & refining of nonferrous metals • New York
CONFIDENTIAL OncoSec Medical Incorporated
Placement Agent Agreement • June 5th, 2014 • ONCOSEC MEDICAL Inc • Services-business services, nec • New York
CONFIDENTIAL Steven P. Nickolas President, Chief Executive Officer and Director The Alkaline Water Company Inc. 7730 East Greenway Road Suite 203 Scottsdale, AZ 85260 Dear Mr. Nickolas:
Placement Agent Agreement • March 12th, 2014 • ALKALINE WATER Co INC • Wholesale-groceries & related products • New York

This letter (the “Agreement”) constitutes the agreement between H.C. Wainwright & Co., LLC. (“HCW” or the “Placement Agent”) and The Alkaline Water Company Inc. (the “Company”), that HCW shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the private or public placement(s) (each, a “Placement”) of one or more classes or series of registered or unregistered securities (the “Securities”) of the Company, including but not limited to an offering off the Company’s filed registration statement on Form S-1 (“S-1 Registration Statement”) pursuant to which the Company seeks to offer and sell registered Securities to investors (such Placement, the “S-1 Offering”). Each Placement may include shares of the Company’s common stock (“Common Stock”), debt, convertible debt, convertible preferred stock and warrants to purchase shares of Common Stock (any such shares of Common Stock or shares of Common Stock underlying any convertible or

CONFIDENTIAL OncoSec Medical Incorporated
Placement Agent Agreement • August 16th, 2013 • ONCOSEC MEDICAL Inc • Services-business services, nec • New York
April 11, 2013
Placement Agent Agreement • May 24th, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
April 11, 2013
Placement Agent Agreement • May 15th, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Chardan Capital Markets, LLC
Placement Agent Agreement • May 9th, 2013 • Senesco Technologies Inc • Services-commercial physical & biological research • New York

This letter (the “Agreement”) constitutes the agreement between Chardan Capital Markets, LLC (“Placement Agent”) and Senesco Technologies, Inc. (the “Company”), that Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $.01 per share (the “Common Stock”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Placement Agent would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers in connection with the

CONFIDENTIAL
Placement Agent Agreement • January 31st, 2013 • Novelos Therapeutics, Inc. • Pharmaceutical preparations • New York

This amended and restated letter (the ”Agreement”) constitutes the agreement between Burrill LLC (“Burrill” or the “Placement Agent”) and Novelos Therapeutics, Inc, (the “Company”), that Burrill shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) and warrants to purchase shares of Common Stock (the “Warrants”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Burrill would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement, the Subscription Agreem

CONFIDENTIAL
Placement Agent Agreement • November 20th, 2012 • Novelos Therapeutics, Inc. • Pharmaceutical preparations • New York

This letter (the “Agreement”) constitutes the agreement between Burrill LLC (“Burrill” or the “Placement Agent”) and Novelos Therapeutics, Inc, (the “Company”), that Burrill shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) and warrants to purchase shares of Common Stock (the “Warrants”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Burrill would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement, the Subscription Agreements (as defined belo

CONFIDENTIAL OncoSec Medical Incorporated
Placement Agent Agreement • November 19th, 2012 • ONCOSEC MEDICAL Inc • Services-business services, nec • New York
CONFIDENTIAL Stephen M. Simes President & Chief Executive Officer BioSante Pharmaceuticals, Inc.
Placement Agent Agreement • August 17th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
CONFIDENTIAL pSivida Corp.
Placement Agent Agreement • August 2nd, 2012 • pSivida Corp. • Laboratory analytical instruments • New York
CONFIDENTIAL James A. Bianco, M.D. Chief Executive Officer Cell Therapeutics, Inc.
Placement Agent Agreement • May 31st, 2012 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
CONFIDENTIAL
Placement Agent Agreement • April 13th, 2012 • Parkervision Inc • Radio & tv broadcasting & communications equipment • New York
CONFIDENTIAL Titan Pharmaceuticals, Inc.
Placement Agent Agreement • April 10th, 2012 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
CONFIDENTIAL
Placement Agent Agreement • April 9th, 2012 • Novelos Therapeutics, Inc. • Pharmaceutical preparations • New York

This letter (the “Agreement”) constitutes the agreement between Rodman & Renshaw, LLC (“Rodman” or the “Placement Agent”) and Novelos Therapeutics, Inc, (the “Company”), that Rodman shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) and warrants to purchase shares of Common Stock (the “Warrants”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Rodman would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement, the Subscription Agreements (as defin

STRICTLY CONFIDENTIAL Marina Biotech, Inc.
Placement Agent Agreement • March 20th, 2012 • Marina Biotech, Inc. • Pharmaceutical preparations • New York
January 31, 2012
Placement Agent Agreement • February 3rd, 2012 • Spherix Inc • Services-engineering, accounting, research, management • New York
AutoNDA by SimpleDocs
CONFIDENTIAL Jones Soda Co.
Placement Agent Agreement • February 2nd, 2012 • Jones Soda Co • Beverages • New York
CONFIDENTIAL Ray Leonard President and Chief Executive Officer Hyperdynamics Corporation 12012 Wickchester Lane, Suite 475 Houston, Texas 77079 Dear Mr. Leonard:
Placement Agent Agreement • February 1st, 2012 • Hyperdynamics Corp • Crude petroleum & natural gas • New York

This letter (the “Agreement”) constitutes the agreement between Rodman & Renshaw, LLC (“Rodman” or the “Placement Agent”) and Hyperdynamics Corporation (the “Company”), that Rodman shall serve as the exclusive placement agent for the Company, on a reasonable best efforts basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and warrants to purchase shares of Common Stock. The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Rodman would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Company and

CONFIDENTIAL OncoSec Medical Incorporated
Placement Agent Agreement • January 24th, 2012 • ONCOSEC MEDICAL Inc • Services-business services, nec • New York
CONFIDENTIAL James A. Bianco, M.D. Chief Executive Officer Cell Therapeutics, Inc.
Placement Agent Agreement • December 14th, 2011 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
CONFIDENTIAL
Placement Agent Agreement • July 22nd, 2011 • Catasys, Inc. • Services-misc health & allied services, nec • New York

This letter (the “Agreement”) constitutes the agreement between Rodman & Renshaw, LLC (“Rodman” or the “Placement Agent”) and Catasys, Inc. (the “Company”), that Rodman shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares of the Company’s common stock, par value $___ per share (the “Shares” or “Common Stock”) [and warrants to purchase shares of Common Stock]. The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Rodman would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchaser

CONFIDENTIAL James A. Bianco, M.D. Chief Executive Officer Cell Therapeutics, Inc.
Placement Agent Agreement • July 6th, 2011 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
CONFIDENTIAL
Placement Agent Agreement • June 21st, 2011 • Cleveland Biolabs Inc • Services-commercial physical & biological research • New York
CONFIDENTIAL James A. Bianco, M.D. Chief Executive Officer Cell Therapeutics, Inc.
Placement Agent Agreement • May 2nd, 2011 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
CONFIDENTIAL Stephen M. Simes President & Chief Executive Officer BioSante Pharmaceuticals, Inc.
Placement Agent Agreement • March 4th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
CONFIDENTIAL
Placement Agent Agreement • February 3rd, 2011 • Dejour Enterprises LTD • Mining & quarrying of nonmetallic minerals (no fuels) • California
Ladenburg Thalmann & Co. Letterhead]
Placement Agent Agreement • January 19th, 2011 • pSivida Corp. • Laboratory analytical instruments • New York
Rodman & Renshaw Letterhead]
Placement Agent Agreement • January 19th, 2011 • pSivida Corp. • Laboratory analytical instruments • New York
CONFIDENTIAL Mr. Zhang Shunqing Chairman and CEO China GengSheng Minerals, Inc. No. 88 Gengsheng Road, Dayugou Town Gongyi, Henan 451271 CHINA Dear Mr. Shunqing:
Placement Agent Agreement • January 10th, 2011 • China Gengsheng Minerals, Inc. • Miscellaneous manufacturing industries • New York

This letter (the “Agreement”) constitutes the agreement between Rodman & Renshaw, LLC (“Rodman” or the “Placement Agent”) and China GengSheng Minerals, Inc. (the “Company”), that Rodman shall serve as the exclusive placement agent for the Company, on a reasonable best efforts basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, consisting of shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and warrants to purchase shares of Common Stock (the “Warrants”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Rodman would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and de

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!